Radspherin

About Oncoinvent

Oncoinvent is a Norwegian clinical-stage radiopharmaceutical company developing Radspherin, a novel alpha-emitting microparticle therapy designed to treat cancers that have spread to body cavities. Founded in Oslo, the company's proprietary technology uses calcium carbonate microparticles containing radium-224 to deliver targeted alpha radiation directly to cancer cells while minimizing damage to healthy tissue. The company's lead candidate Radspherin has received FDA Fast Track Designation for peritoneal carcinomatosis from ovarian cancer and is currently in a randomized Phase 2b trial across the US and Europe. Early clinical data has been highly encouraging, with no dose-limiting toxicity observed at the recommended dose. Oncoinvent is publicly traded on the Oslo Stock Exchange (ticker: OCI) and is actively seeking strategic partnerships to expand its pipeline.

About Oncoinvent

Oncoinvent is a Norwegian clinical-stage radiopharmaceutical company developing Radspherin, a novel alpha-emitting microparticle therapy designed to treat cancers that have spread to body cavities. Founded in Oslo, the company's proprietary technology uses calcium carbonate microparticles containing radium-224 to deliver targeted alpha radiation directly to cancer cells while minimizing damage to healthy tissue. The company's lead candidate Radspherin has received FDA Fast Track Designation for peritoneal carcinomatosis from ovarian cancer and is currently in a randomized Phase 2b trial across the US and Europe. Early clinical data has been highly encouraging, with no dose-limiting toxicity observed at the recommended dose. Oncoinvent is publicly traded on the Oslo Stock Exchange (ticker: OCI) and is actively seeking strategic partnerships to expand its pipeline.

Therapeutic Areas